參考文獻/References:
[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
[2] GANESAN P,KULIK L M.Hepatocellular Carcinoma[J].Clinics in Liver Disease,2023,27(1):85-102.
[3] 王維德.外科證治全生集[M].北京:人民衛(wèi)生出版社,2006:36.
[4] 周云娣.西黃丸輔助治療晚期原發(fā)性肝癌效果觀察[J].臨床合理用藥雜志,2020,13(4):73-75.
[5] WU J S,NIU Q,YUAN J,et al.Novel compound cedrelone inhibits hepatocellular carcinoma progression via PBLD and Ras/Rap1[J].Exp Ther Med,2019,18(6):4209-4220.
[6] ZHANG B C,YIN X N,SUI S G.Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3-kinase/protein kinase B pathway[J].Oncol Rep,2018,40(5):2758-2765.
[7] JIANG Y,QIAN Y,HONG H,et al.Morin protects chicks with T-2 toxin poisoning by decreasing heterophil extracellular traps,oxidative stress and inflammatory response[J].Br Poult Sci,2023,64(5):614-624.
[8] SIVARAMAKRISHNAN V,DEVARAJ S N.Morin fosters apoptosis in experimental hepatocellular carcinogenesis model[J].Chem Biol Interact,2010,183(2):284-292.
[9] MONTGOMERY E J,XING E,CAMPBELL M J,et al.Constitutively active androgen receptor in hepatocellular carcinoma[J].Int J Mol Sci,2022,23(22):13768.
[10] DAUKI A M,BLACHLY J S,KAUTTO E A,et al.Transcriptionally active androgen receptor splice variants promote hepatocellular carcinoma progression[J].Cancer Res,2020,80(3):561-575.
[11] COCCIADIFERRO L,MICELI V,GRANATA O M,et al.Merlin,the product of NF2 gene,is associated with aromatase expression and estrogen formation in human liver tissues and liver cancer cells[J].J Steroid Biochem Mol Biol,2017,172:222-230.
[12] JEON Y,YOO J E,RHEE H,et al.YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior[J].Exp Mol Med,2021,53(6):1055-1067.
[13] MATSUSHIMA-NISHIWAKI R,YAMADA N,HATTORI Y,et al.SERMs(selective estrogen receptor modulator),acting as estrogen receptor β agonists in hepatocellular carcinoma cells,inhibit the transforming growth factor-α-induced migration via specific inhibition of AKT signaling pathway[J].PLoS One,2022,17(1):e0262485.
[14] MOON H,RO S W.MAPK/ERK signaling pathway in hepatocellular carcinoma[J].Cancers(Basel),2021,3(12):3026-3045.
[15] HAO Y L,FANG H C,ZHAO H L,et al.The role of microRNA-1 targeting of MAPK3 in myocardial ischemia-reperfusion injury in rats undergoing sevoflurane preconditioning via the PI3K/Akt pathway[J].Am J Physiol Cell Physiol,2018,315(3):380-388.
相似文獻/References:
[1]許揚梅 龔福生 劉沁穎 劉施佳 黃麗潔 鄭秋紅.MiR-194過表達和抑制表達對肝癌細胞株Hep-3b中側群細胞增殖的影響[J].福建醫(yī)藥雜志,2019,41(06):141.
XU Yangmei,GONG Fusheng,LIU Qinying,et al.Influence of miR-194 up and down-expression on liver cancer stem cells[J].FUJIAN MEDICAL JOURNAL,2019,41(02):141.
[2]黃雪平,王明霞,江麗鳳,等.慢性乙型肝炎病毒感染患者血清sPD-1檢測的臨床意義[J].福建醫(yī)藥雜志,2022,44(03):8.
HUANG Xueping,WANG Mingxia,JIANG Lifeng,et al.Detection and clinical significance of soluble programmed death factor-1 in patients with chronic viral hepatitis B[J].FUJIAN MEDICAL JOURNAL,2022,44(02):8.